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Abstract: Background An appropriate and adequate blood flow and oxygen delivery is paramount to free
flap viability and success. The perioperative use of tranexamic acid (TXA) is associated with less risk
for blood loss and blood transfusion in trauma, gynaecology, ear nose and throat (ENT) and orthopaedic
surgery. As an antifibrinolytic drug, TXA has generally been avoided in microsurgery. The aim of this
study is to evaluate the safety and benefit of using TXA in microsurgery. Methods We performed a
retrospective single centre cohort study at the Pyramid Clinic, Zurich, Switzerland, including 98 free
tissue transfers for breast reconstruction from 2011 to 2013. According to the estimated blood loss, up to
3 g TXA were administered intravenously in 63 free flaps perioperatively. Results No thrombosis (0%)
of micro-anastomosis and 5 haematomas (10.0%) occurred after administration of TXA. In the control
group, 1 thrombosis (3.0%) of a flap-vein and 6 haematomas (18.2%) occurred. Blood loss was significant
lower (P<0.001) after administration of TXA. Conclusions In this study, administration of TXA did
not increase thrombosis in free tissue transfer and showed a reduced haematoma rate and significant
reduction of blood loss. TXA is supposed to be safe and a reasonable adjunct for patients with anaemia
and a higher intraoperative or postoperative blood loss.
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Introduction
Free tissue transfer for breast reconstruction rarely involves 
significant blood loss (1,2). However, our patients are 
generally cancer patients and do present with pre-existing 
anaemia related to their cancer or its treatment (3,4). An 
appropriate and adequate blood flow and oxygen delivery 
is paramount to free flap viability and success (5). The 
perioperative use of tranexamic acid (TXA) is associated 
with less risk for blood loss and transfusion in trauma, 
gynaecology, ear nose and throat (ENT) and orthopaedic 
surgery (6-9). In a meta-analysis of surgical trials including 
10,488 patients, the risk for transfusion was reduced by 
38% in the TXA group, with no significant differences in 
mortality or thrombotic events (10). As an antifibrinolytic 
drug, TXA has generally been avoided in microsurgery. In 
literature, there is an inconsistent evidence for increased 
risk for thromboembolic complications (9,11). Also, at 
present still no consensus has been established on treatment 
guidelines in terms of ideal antithrombotic agents, timing, 
and dosage in reconstructive microsurgery (12-14). Low-
molecular heparin in a recent literature review Brinkman 
et al. was recommended as monotherapy, as this seems to 
be as effective as acetylsalicylic acid, and has the additional 
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advantage to prevent systemic thromboembolic events, 
and unlike acetylsalicylic acid does not increase the risk of 
gastrointestinal bleeding (12).
The aim of this study is to evaluate the safety and benefit 
of using TXA in microsurgery.
Methods
We performed a retrospective single centre cohort study 
from October 2011 until October 2013, including free 
tissue transfer for immediate breast reconstruction. 
This study represents a single-surgeon experience. The 
procedures were performed with a uniform protocol: 
low-molecular heparin, Enoxaparine, (Clexane®, Sanofi-
Aventi )  was administered in prophylact ic  dosage 
(40 mg s.c.) starting 12 hours before procedure and once 
daily until discharge as antithrombotic monotherapy. 
Neither intraoperative heparin nor postoperative 
acetylsalicylic acid was administered (12-14). Experienced 
senior breast surgeons performed the mastectomies via 
sharp dissection. No tumescent solution was used.
During period 1 (first 12 months), no TXA was 
administered. During period 2 (second 12 months), up 
to 3 g TXA were administered intravenously according 
to the estimated blood loss, both intraoperatively and/or 
postoperatively. The intraoperative blood loss was estimated 
on the amount of blood in the suction container and by 
the senior author evaluating swaps and blood loss on table 
twice, once after mastectomy was finished, and once after 
anastomosis was done. If intraoperative blood loss was 
estimated >100 mL from last measurement, 1 g TXA was 
administered. The postoperative blood loss during first 
24 hours was estimated from drain output. If drain output 
was fresh blood >200 mL per hour another dosage of 1g 
TXA was given till 24 hours after procedure.
Blood transfusions were administered if Hb <8 g/L or 
if patients became symptomatic for anaemia. Patients with 
a known tendency for thromboembolic complications and 
thromboembolic events in their personal history were 
excluded. We also excluded delayed breast reconstructions, 
because of low number and to gain uniform procedure 
characteristics.
Data collection and analysis
Patient demographic data including age, body mass index, 
diabetes, current tobacco use, chemotherapy (neoadjuvant 
or adjuvant) and radiotherapy, as well as procedure specific 
parameters (type of flap performed, flap weight, ischemia 
time, intraoperative problems) were collected from hospital 
records.
Postoperative complications [haematoma, thrombosis, 
flap loss, blood transfusion, deep venous thrombosis 
(DVT), pulmonary embolism (PE)] were recorded, as well 
as intraoperative and postoperative blood loss during first 
24 hours. 
The two-groups t-test was used for continuous data, 
the Chi-square test for categorical data and the Fisher test 
for binary data. Exact confidence intervals for rates were 
calculated assuming a binomial distribution. The impact of 
risk factors on the occurrence of haematoma was analysed 
using a univariate logistic model. A value of P<0.05 was 
considered significant.
Two patients contributed data from two different 
procedures, once with use of TXA and once without TXA. 
The data of the two procedures was treated as independent 
observations in the analysis of complications. For the 
analysis of risk factors, only the data from the procedure 
without use of TXA was used. For the analysis of blood loss 
an ANOVA with factors for treatment, flap type and the 
corresponding interaction was used.
Results
Over the 2-year study period, the senior author performed 
100 free flaps for immediate breast reconstruction on 85 
patients. We excluded two patients/free flaps for DVT in 
their medical history. Ninety-eight free flaps in 83 patients 
were included. In the treatment group, 50 patients and 63 
free flaps were included, 33 patients and 35 free flaps in the 
control group. See demographic data in Table 1.
In total, 98 mastectomies were performed, of which 82 
for oncological reasons and 16 for risk-reduction. In the 
study population, 48 deep inferior epigastric perforator 
(DIEP) flaps, 10 profunda artery perforator (PAP) flaps, 
25 transverse myocutaneous gracilis (TMG) flaps and 15 
superior gluteal artery (S-GAP) flaps were performed. Flap 
characteristics are summarised in Table 2.
Revision surgery was performed in 21 cases (21.4%), 
of which 19 were successful without flap loss. Eleven flaps 
(11.2%) were revised due to haematoma at the flap side. 
In three cases a kinking of the pedicle was found. One 
patient was brought back to theatres due to hypothermia 
of the flap, with no cause found in revision surgery. Three 
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flaps showed venous congestion, two because of inadequate 
venous outflow and no thrombosis was found. In these 
two cases an additional venous drainage resolved the 
impairment. In one case (DIEP) of venous congestion a 
thrombosis of the micro-anastomosis of the vein caused the 
clinical impairment, the thrombosis was removed and the 
venous anastomosis redone. In one free flap (S-GAP) the 
micro-anastomosis of the artery was redone for technical 
problems.
Flap loss occurred in two cases (2%). In these two flaps 
(one S-GAP, one DIEP) the perforator was too small and 
insufficient for flap supply and flaps were lost. 
Table 3 shows distribution of complications for TXA and 
control group.
Discussion
Only one thrombosis of a micro-anastomosis of a vein 
occurred in the study population (control group). In this 
study, the administration of TXA did not increase the risk 
of thrombosis. Haematoma rate (P=0.332) was reduced in 
the Tranexamic group. However, in this study, haematoma 
rate was higher compared to the literature (1,2,15). In the 
senior author’s practise, the decision for revision surgery 
is taken early before a developing haematoma may impair 
flap survival. In all haematoma revisions no real source was 
found. Evaluating the risk factors for haematoma in this 
study, not only the avoidance of the use of TXA (P=0.398), 
but also neoadjuvant chemotherapy (P=0.333), smoking 
(P=0.165) and higher age (P=0.035) showed to be risk 
factors for the occurrence of haematoma (Table 4). 
Intraoperative and blood loss during the first 24 hours 
was reduced significantly (P<0.001) with the use of TXA. 
Only one patient in the study group needed a blood 
transfusion (TXA group). The patients in the control 
group, although with higher blood loss, did not need blood 
transfusion. 
TXA in this study did not increase thrombosis and 
was able to reduce bleeding. This creates a new option 
in pharmaceutical treatment of surgical bleeding in 
free flap surgery, without putting at risk microsurgical 
anastomosis. Nevertheless, in our opinion, TXA must not 
be used in a prophylactic manner, considering most of the 
patients and flaps being able to deal with the blood loss 
without treatment. Yet for patients with anaemia and a 
higher intraoperative or postoperative blood loss, TXA is 
Table 1 Patient demographics and clinical characteristics
Variables Total TXA Control group P value
Patients, N 83 50 33 –
Flaps, N 98 63 35 –
Age (years), mean (SD) 51.1 (8.8) (N=83) 51.4 (9.2) (N=50) 50.6 (8.4) (N=33) 0.679*
BMI (kg/m
2
), mean (SD) 22.4 (3.1) (N=48) 22.7 (3.0) (N=33) 21.7 (3.2) (N=15) 0.300*
Bilateral flaps, N (% patients) 15 (18.1) 13 (26.0) 2 (6.1) 0.022**
Current tobacco use, N (% patients) 6 (7.2) 5 (10.0) 1 (3.0) 0.395**
Diabetes, N 0 0 0 –
Neoadjuvant chemotherapy, N (% patients) 8 (9.6) 6 (12.0) 2 (6.1) 0.468**
Previous irradiation, N (% flaps) 23 (23.5) 14 (22.2) 8 (22.9) 1.000**
*, Student’s t-test; **, Fisher test. TXA, tranexamic acid.




Flap type, N (%)
DIEP 31 (49.2) 17 (48.6)
PAP 7 (11.1) 3 (8.6)
TMG 12 (19.0) 13 (37.1)
S-GAP 13 (20.6) 2 (5.7)
Flap weight, mean [SD] (g) 405 [151] 361 [172]
Ischemia time, mean (SD) (min) 65.2 (26.4) 57.9 (16.2)
DIEP, deep inferior epigastric perforator; PAP, profunda artery 
perforator; TMG, transverse myocutaneous gracilis; S-GAP, 
superior gluteal artery; TXA, tranexamic acid.
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Table 3 Complications TXA versus control group
Complications TXA (N=50) Control group (N=33) P value
Thrombosis of anastomosis (vein or artery), N [% patients (95% CI)] 0 [0 (0.0–7.3)] 1 [3.0 (vein) (0.1–15.8)] 0.398**
DVT, N 0 0 –
Blood loss, mean (SD) (mL)* 158.4 (53.8) 231.5 (76.2) <0.001***
Haematoma breast, N [% patients (95% CI)] 5 [10.0 (3.3–21.8)] 6 [18.2 (7.0–35.5)] 0.332**
Haematoma donor side, N 0 0 –
Blood transfusion, N [% patients (95% CI)] 1 [2.0 (0.1–10.7)] 0 [0.0 (0.0–10.6)] 1.000**
Flap loss, N [% patients (95% CI)] 2 [4.0 (0.5–13.7)] 0 [0.0 (0.0–10.6)] 0.515**
*, blood loss, sum of intraoperative blood loss and drainage in first 24 hours postop; **, Fisher test; ***, ANOVA. TXA, tranexamic acid.
Table 4 Hematoma risk factors
Risk factors Total number
Haematoma
Number % Odds ratio* (95% CI) P value**
Treatment 1.91 (0.53–6.88) 0.322
TXA 48 5 10.4
Control 33 6 18.2
Previous radiotherapy 0.64 (0.13–3.25) 0.593
No 61 9 14.8
Yes 20 2 10.0
Neoadjuvant chemotherapy 2.37 (0.41–13.58) 0.333
No 73 9 12.3
Yes 8 2 25.0
Smoker 3.67 (0.59–22.97) 0.165
No 75 9 12.0
Yes 6 2 33.3
Flap type 5.80 (1.52–22.15) 0.010
DIEP 45 3 6.7
PAP 7 1 14.3
TMG 18 6 33.3
S-GAP 11 1 9.1
Age 10.00 (1.18–84.76) 0.035
≤50 years 38 1 2.6
>50 years 43 8 18.6
For two patients with multiple procedures the data from the procedure without use of TXA only were used. *, odds ratio was calculated 
as second versus first category, for flap type as TMG versus other types; **, univariate logistic regression. DIEP, deep inferior epigastric 
perforator; PAP, profunda artery perforator; TMG, transverse myocutaneous gracilis; S-GAP, superior gluteal artery; TXA, tranexamic acid.
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considered a reasonable adjunct.
Conclusions
In this study, administration of TXA did not increase 
thrombosis in free tissue transfer and showed a reduced 
haematoma rate and significant reduction of blood loss. 
TXA is supposed to be safe and a reasonable adjunct 
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